The choice isn't that hard.

Novo Nordisk has global metabolic leadership, an oral GLP-1 program, and a stock price below $50 after a retail-driven ...

By Harshita Mary Varghese and Patrick Wingrove Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million on U.S. advertising ...

The target action date for orforglipron is now April 10.

Novo Nordisk sharply increased U.S. advertising for Wegovy and Ozempic in 2025, outspending Eli Lilly as competition for obesity drugs intensified.

We look at the Novo Nordisk A/S outlook for 2026: new CEO focus, oral Wegovy edge vs Eli Lilly, and double-digit growth ...

Strive Specialities Inc., a major provider of compounded medicines, filed a federal lawsuit against pharmaceutical giants Eli Lilly & Co. and Novo Nordisk Inc. The 49-page antitrust lawsuit, filed in ...

Novo Nordisk oral Wegovy records 3,071 prescriptions in four days. Shares jump 6.5% as Eli Lilly oral weight loss drug awaits ...

Lilly CEO Dave Ricks is confident in the ability of the company's pill to compete and is preparing for a "full launch" in the second quarter.

Wegovy, Ozempic, and Zepbound makers will show up in and around the Big Game.

In 2026, new obesity pills will push the booming GLP-1 market into its next chapter. Pills may serve as a more convenient — and in certain cases cheaper — alternative to today's blockbuster injections ...